For Release October 1, 2009
Doctors Volkow and Kosten will discuss the findings of a study in the October issue of Archives of General Psychiatry evaluating the safety and efficacy of a vaccine to treat cocaine addiction. Currently there is no FDA-approved medication for treating cocaine addiction.
Teleconference on newly released results from a National Institute on Drug Abuse sponsored trial of an anti-cocaine treatment vaccine
NIDA Director Dr. Nora Volkow and lead investigator, Dr. Thomas Kosten, Baylor College of Medicine
Monday, October 5th
4:00 to 5:00pm Eastern Daylight Time. EST
Operator assisted live dial-in event at: 888-567-1602 (U.S. and Canada) or
(201) 604-5049 (international callers).
The National Institute on Drug Abuse is a component of the National Institutes of Health, U.S. Department of Health and Human Services. NIDA supports most of the world’s research on the health aspects of drug abuse and addiction. The Institute carries out a large variety of programs to inform policy and improve practice. Fact sheets on the health effects of drugs of abuse and information on NIDA research and other activities can be found on the NIDA home page at www.drugabuse.gov. To order publications in English or Spanish, call NIDA’s new DrugPubs research dissemination center at 1-877-NIDA-NIH or 240-645-0228 (TDD) or fax or email requests to 240-645-0227 or drugpubs@nida.nih.gov. Online ordering is available at
http://drugpubs.drugabuse.gov.
The National Institutes of Health (NIH) — The Nation's Medical Research Agency — includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. It is the primary Federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
The Substance Abuse and Mental Health Services Administration (SAMHSA) is a public health agency also within the Department of Health and Human Services. The agency is responsible for improving the accountability, capacity and effectiveness of the nation's substance abuse prevention, addictions treatment, and mental health services delivery system.
The White House Office of National Drug Control Policy (ONDCP), a component of the Executive Office of the President, was established by the Anti-Drug Abuse Act of 1988. The principal purpose of ONDCP is to establish policies, priorities, and objectives for the Nation's drug control program. The goals of the program are to reduce illicit drug use, manufacturing, and trafficking, drug-related crime and violence, and drug-related health consequences.
|
